US DHHS Guidelines with Australian commentary
Characteristics of the CCR5 Antagonist
Last Updated: October 25, 2018; Last Reviewed: October 25, 2018
|Formulations||Dosing Recommendationsa||Serum Half-Life||Elimination/
||14-18 hours||CYP3A4 substrate||
|a For dosage adjustment in patients with hepatic insufficiency, see Appendix B, Table 8.
b Also see Table 15.
Key to Acronyms: BID = twice daily; CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; T-20 = enfuvirtide; TPV/r = tipranavir/ritonavir